表紙
市場調查報告書

全球胃輕癱(gastroparesis)藥物市場:2017∼2021年

Global Gastroparesis Drugs Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 498811
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
全球胃輕癱(gastroparesis)藥物市場:2017∼2021年 Global Gastroparesis Drugs Market 2017-2021
出版日期: 2017年05月03日內容資訊: 英文 70 Pages
簡介

全球胃輕癱藥物市場預測在2017∼2021年間,將以年複合成長率3.54%擴大。由於疾病或受傷造成迷走神經損傷,可能導致胃輕癱。雖然無法完全緩解,但適當的藥物以及飲食變化可以稍事緩解。

本報告提供全球胃輕癱藥物市場相關調查,彙整各疾病,各類藥物,地區別趨勢,競爭趨勢,主要供應商簡介等資料。

第1章 執行摘要

第2章 本報告的範圍

第3章 調查方法

第4章 簡介

第5章 疾病概要

第6章 市場情況

  • 市場概要
  • 波特的五力分析

第7章 開發平台環境

第8章 各疾病市場區隔

  • 糖尿病性
  • 突發性
  • 其他

第9章 各類藥物市場區隔

  • 運動催化劑
  • 抗嘔吐藥
  • 肉毒桿菌注射

第10章 各地區市場市場區隔

  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第11章 決策架構

第12章 促進要素與課題

第13章 市場趨勢

  • 快速通過批准和收購來改變市場階段
  • 引進治療胃輕癱症狀的新方法

第14章 供應商環境

  • 競爭模式
  • Cadila Pharmaceuticals
  • GlaxoSmithKline
  • Johnson & Johnson
  • Valeant
  • 其他值得注意的供應商

第15章 附錄

目錄
Product Code: IRTNTR13089

About Gastroparesis Drugs

Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. Normally, the vagus nerve controls the stomach muscles, which are responsible for the movement of food in the stomach. These muscles contract to break up the food and lead to its movement through the gastrointestinal tract. Gastroparesis can be caused due to the damage of vagus nerve by illness or injury. The disease does not have complete remission; however, proper medications along with the changes in diet can provide relief.

Technavio's analysts forecast the global gastroparesis drugs market to grow at a CAGR of 3.54% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global gastroparesis drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Gastroparesis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Cadila Pharmaceuticals
  • GlaxoSmithKline
  • Johnson & Johnson
  • Valeant

Other Prominent Vendors

  • Evoke Pharma
  • Teva Pharmaceutical Industries
  • Theravance Biopharma

Market driver

  • Rising cases of diabetes fueling the prevalence of diabetic gastroparesis.
  • For a full, detailed list, view our report

Market challenge

  • Difficulty in diagnosis is hampering the medication process.
  • For a full, detailed list, view our report

Market trend

  • Introduction of novel ways for the treatment of gastroparesis symptoms.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

PART 06: Market landscape

  • Market overview
  • Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by disease type

  • Diabetic gastroparesis
  • Idiopathic gastroparesis
  • Others

PART 09: Market segmentation by drug class

  • Prokinetic agents
  • Antiemetic agents
  • Botulinum toxin injection

PART 10: Geographical segmentation

  • Gastroparesis drugs market in Americas
  • Gastroparesis drugs market in EMEA
  • Gastroparesis drugs market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges

  • Market drivers
  • Market challenges

PART 13: Market trends

  • Fast track approvals and acquisitions to change the phase of the market
  • Introduction of novel ways for the treatment of gastroparesis symptoms

PART 14: Vendor landscape

  • Competitive scenario
  • Cadila Pharmaceuticals
  • GlaxoSmithKline
  • Johnson & Johnson
  • Valeant
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Causes of gastroparesis
  • Exhibit 02: Major complications associated with gastroparesis
  • Exhibit 03: Diagnosis and treatment of gastroparesis
  • Exhibit 04: Global gastroparesis drugs market snapshot
  • Exhibit 05: Global gastroparesis drug market 2016-2021 ($ millions)
  • Exhibit 06: Opportunity analysis in global gastroparesis drugs market
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Pipeline summary based on vendors
  • Exhibit 09: Key clinical trials
  • Exhibit 10: Segmentation of global gastroparesis drugs market by disease type 2016
  • Exhibit 11: Global gastroparesis drugs market share by disease type 2016 (%)
  • Exhibit 12: Market snapshot: Global gastroparesis drugs market 2016-2021
  • Exhibit 13: Function of vagus nerves in digestive system
  • Exhibit 14: Global diabetic gastroparesis drugs market 2016-2021 ($ millions)
  • Exhibit 15: Global idiopathic gastroparesis drugs market 2016-2021 ($ millions)
  • Exhibit 16: Other causes of gastroparesis
  • Exhibit 17: Global gastroparesis drugs market by other causes 2016-2021 ($ millions)
  • Exhibit 18: Segmentation of global gastroparesis drug market by drug class
  • Exhibit 19: Market analysis of gastroparesis drug class
  • Exhibit 20: Global gastroparesis drugs market based on geography 2016 and 2021
  • Exhibit 21: Global gastroparesis drugs market revenue by geography 2016-2021 ($ millions)
  • Exhibit 22: Market scenario in Americas
  • Exhibit 23: Gastroparesis drugs market in the Americas 2016-2021 ($ millions)
  • Exhibit 24: Top American countries with diabetic population range (millions)
  • Exhibit 25: Market scenario in EMEA
  • Exhibit 26: Gastroparesis drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 27: Market scenario in APAC
  • Exhibit 28: Top Asian countries with diabetic population range (millions)
  • Exhibit 29: Gastroparesis drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 30: New cases of diabetes by 2040
  • Exhibit 31: Possible treatments for gastroparesis.
  • Exhibit 32: Alternate treatment options for gastroparesis
  • Exhibit 33: Factors affecting the diagnosis of gastroparesis
  • Exhibit 34: Strategic success factors of companies in global gastroparesis drug market
  • Exhibit 35: Competitive structure analysis of global gastroparesis market
  • Exhibit 36: Cadila Pharmaceuticals: Key highlights
  • Exhibit 37: Cadila Pharmaceuticals: Strength assessment
  • Exhibit 38: Cadila Pharmaceuticals: Strategy assessment
  • Exhibit 39: Cadila Pharmaceuticals: Opportunity assessment
  • Exhibit 40: GlaxoSmithKline: Key highlights
  • Exhibit 41: GlaxoSmithKline: Strength assessment
  • Exhibit 42: GlaxoSmithKline: Strategy assessment
  • Exhibit 43: GlaxoSmithKline: Opportunity assessment
  • Exhibit 44: Johnson & Johnson: Key highlights
  • Exhibit 45: Johnson & Johnson: Strength assessment
  • Exhibit 46: Johnson & Johnson: Strategy assessment
  • Exhibit 47: Johnson & Johnson: Opportunity assessment
  • Exhibit 48: Valeant: Key highlights
  • Exhibit 49: Valeant: Strength assessment
  • Exhibit 50: Valeant: Strategy assessment
  • Exhibit 51: Valeant: Opportunity assessment